Evoke Pharma Inc (EVOK) Receives Average Rating of “Buy” from Analysts

Evoke Pharma Inc (NASDAQ:EVOK) has been given a consensus rating of “Buy” by the ten brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $9.00.

EVOK has been the topic of several recent research reports. FBR & Co reissued a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a research note on Monday, October 30th. ValuEngine downgraded Evoke Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research raised Evoke Pharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 12th. Seaport Global Securities reissued a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a research note on Friday, October 6th. Finally, Northland Securities reissued a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a research note on Wednesday, October 18th.

Evoke Pharma (NASDAQ EVOK) traded down $0.05 on Friday, hitting $2.66. The company’s stock had a trading volume of 84,044 shares, compared to its average volume of 74,969. Evoke Pharma has a 1 year low of $2.19 and a 1 year high of $4.55. The firm has a market cap of $41.00, a P/E ratio of -2.83 and a beta of 1.09.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.13). During the same quarter in the previous year, the business earned ($0.29) earnings per share. equities analysts forecast that Evoke Pharma will post -1 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Creative Planning bought a new position in shares of Evoke Pharma in the 4th quarter valued at about $226,000. Vanguard Group Inc. grew its holdings in shares of Evoke Pharma by 15.1% in the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after acquiring an additional 68,544 shares in the last quarter. Finally, Sphera Funds Management LTD. grew its holdings in shares of Evoke Pharma by 14.2% in the 3rd quarter. Sphera Funds Management LTD. now owns 571,022 shares of the specialty pharmaceutical company’s stock valued at $1,907,000 after acquiring an additional 71,022 shares in the last quarter. Institutional investors own 13.64% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/19/evoke-pharma-inc-evok-receives-average-rating-of-buy-from-analysts.html.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply